Zymeworks Inc.

As of June 30, 2026, Zymeworks Inc. carries a market capitalization of 1.65B, placing it among publicly traded companies globally. Its enterprise value stands at 1.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zymeworks Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Zymeworks Inc. has 71.96M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 52.79, and the price-to-book ratio stands at 23.50.

These figures are as of June 30, 2026. The EV/Sales ratio of 44.00 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.43B versus a market cap of 1.65B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zymeworks Inc. maintains a current ratio of 6.32, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.92, indicating elevated leverage, while an interest coverage ratio of -16.88 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zymeworks Inc. posted a negative return on equity (ROE) of -72.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.25, reflecting losses generated across the asset base. The company generates approximately 120,583.54 in revenue per employee across its workforce of 269.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Zymeworks Inc. recorded an income tax benefit of -1.22M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -132.51M and -131.29M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Zymeworks Inc.'s stock has gained approximately 65.99% over the past 52 weeks. The 50-day moving average sits at 23.67, while the 200-day moving average is 21.70.

Over the twelve months ended June 30, 2026, Zymeworks Inc. generated 32.50M in revenue and converted that into -131.29M in net income, yielding earnings per share of -1.76. EBITDA reached -127.94M, while operating income came in at -136.09M.

As of June 30, 2026, Zymeworks Inc. holds 236.94M in cash and equivalents against 14.01M in total debt, resulting in a net debt position of -157.04M. Total book value stands at 70.35M, with working capital of 219.83M providing operational flexibility.

Zymeworks Inc. produced -104.46M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.18M in capital expenditures, free cash flow totaled -105.63M - equivalent to -1.41 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -418.77 and net profit margin of -404.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.16: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.70, meaning Zymeworks Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Zymeworks Inc. has an Altman Z-Score of -1.15, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.